294 related articles for article (PubMed ID: 34680101)
1. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.
Wang S; Zheng Y; Yang F; Zhu L; Zhu XQ; Wang ZF; Wu XL; Zhou CH; Yan JY; Hu BY; Kong B; Fu DL; Bruns C; Zhao Y; Qin LX; Dong QZ
Signal Transduct Target Ther; 2021 Jul; 6(1):249. PubMed ID: 34219130
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
8. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors related with survival in patients with pancreatic adenocarcinoma.
Bilici A
World J Gastroenterol; 2014 Aug; 20(31):10802-12. PubMed ID: 25152583
[TBL] [Abstract][Full Text] [Related]
10. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the management of pancreatic adenocarcinoma.
Karakas Y; Lacin S; Yalcin S
Expert Rev Anticancer Ther; 2018 Jan; 18(1):51-62. PubMed ID: 29125367
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.
Xia T; Chen XY; Zhang YN
Mol Cell Biochem; 2021 Dec; 476(12):4191-4203. PubMed ID: 34324119
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
18. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma.
Zheng X; Liu X; Zheng H; Wang H; Hong D
Int Immunopharmacol; 2021 Jan; 90():106982. PubMed ID: 33129696
[TBL] [Abstract][Full Text] [Related]
19. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
20. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
